p.162 抽出テキスト

378: 41-48. PMID: 21703676 215. Barco S, Schmidtmann I, Ageno W, et al. HoT-PE Investigators. Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial. Eur Heart J 2020; 41: 509-518. PMID: 31120118 216. Chatani R, Yamashita Y, Morimoto T, et al. ONCO PE Trial Investigators. Home treatment for active cancer patients with low-risk pulmonary embolism A predetermined companion report from the ONCO PE trial. Circ J 2024 Mar 8. Online ahead of print. PMID: 38462535 217. Ota M, Nakamura M, Yamada N, et al. Association between antithrombotic treatments and prognosis of patients with acute pulmonary thromboembolism in Japan. Circ J 2003; 67: 612-616. PMID: 12845185 218. Lyhne MD, Hansen JV, Dragsbæk SJ, et al. Oxygen therapy lowers right ventricular afterload in experimental acute pulmonary embolism. Crit Care Med 2021; 49: e891-e901. PMID: 33870917 219. Marwah V, Shafin Babu PS, Katoch CDS, et al. Effectiveness of high flow nasal cannula oxygen therapy in patients of acute pulmonary thromboembolism with acute hypoxemic respiratory failure. Med J Armed Forces India 2022; 78: 448-453. PMID: 36267512 220. Molloy WD, Lee KY, Girling L, et al. Treatment of shock in a canine model of pulmonary embolism. Am Rev Respir Dis 1984; 130: 870-874. PMID: 6497165 221. Ghignone M, Girling L, Prewitt RM. Volume expansion versus norepinephrine in treatment of a low cardiac output complicating an acute increase in right ventricular afterload in dogs. Anesthesiology 1984; 60: 132-135. PMID: 6198941 222. Goldhaber SZ. Pulmonary embolism. In: Braunwald E, Zipes DP, Libby P, editors. Heart disease, 6th edn. Saunders, 2001: 1886-1907. 223. Mercat A, Diehl JL, Meyer G, et al. Hemodynamic effects of fluid loading in acute massive pulmonary embolism. Crit Care Med 1999; 27: 540-544. PMID: 10199533 224. De Backer D, Biston P, Devriendt J, et al. SOAP II Investigators. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010; 362: 779-789. PMID: 20200382 225. Jardin F, Genevray B, Brun-Ney D, et al. Dobutamine: a hemodynamic evaluation in pulmonary embolism shock. Crit Care Med 1985; 13: 1009-1012. PMID: 4064710 226. Manier G, Castaing Y. Influence of cardiac output on oxygen exchange in acute pulmonary embolism. Am Rev Respir Dis 1992; 145: 130-136. PMID: 1731576 227. Tanaka H, Tajimi K, Matsumoto A, et al. Vasodilatory effects of milrinone on pulmonary vasculature in dogs with pulmonary hypertension due to pulmonary embolism: a comparison with those of dopamine and dobutamine. Clin Exp Pharmacol Physiol 1990; 17: 681-690. PMID: 2272126 228. Böttiger BW, Motsch J, Dörsam J, et al. Inhaled nitric oxide selectively decreases pulmonary artery pressure and pulmonary vascular resistance following acute massive pulmonary microembolism in piglets. Chest 1996; 110: 1041-1047. PMID: 8874266 229. Capellier G, Jacques T, Balvay P, et al. Inhaled nitric oxide in patients with pulmonary embolism. Intensive Care Med 1997; 23: 1089-1092. PMID: 9407246 230. Bhat T, Neuman A, Tantary M, et al. Inhaled nitric oxide in acute pulmonary embolism: a systematic review. Rev Cardiovasc Med 2015; 16: 1-8. PMID: 25813791 231. Minakawa M, Fukuda I, Miyata H, et al. Japan Cardiovascular Surgery Database Organization. Outcomes of pulmonary embolectomy for acute pulmonary embolism. Circ J 2018; 82: 2184-2190. PMID: 29952349 232. Rivers J, Pilcher D, Kim J, et al. Extracorporeal membrane oxygenation for the treatment of massive pulmonary embolism. An analysis of the ELSO database. Resuscitation 2023; 191: 109940. PMID: 37625576 233. Kaso ER, Pan JA, Salerno M, et al. Venoarterial extracorporeal membrane oxygenation for acute massive pulmonary embolism: a meta-analysis and call to action. J Cardiovasc Transl Res 2022; 15: 258-267. PMID: 34282541 234. Sakuraya M, Hifumi T, Inoue A, et al. SAVE-J II Study Group. Neurological outcomes and reperfusion strategies in out-of-hospital cardiac arrest patients due to pulmonary embolism who underwent venoarterial extracorporeal membrane oxygenation: A post-hoc analysis of a multicenter retrospective cohort study. Resuscitation 2023; 191: 109926. PMID: 37544497 235. Chopard R, Nielsen P, Ius F, et al. Optimal reperfusion strategy in

acute high-risk pulmonary embolism requiring extracorporeal membrane oxygenation support: a systematic review and meta-analysis. Eur Respir J 2022; 60: 35487534. PMID: 35487534 236. Nishimoto Y, Ohbe H, Matsui H, et al. Effectiveness of systemic

thrombolysis on clinical outcomes in high-risk pulmonary embolism patients with venoarterial extracorporeal membrane oxygenation: a nationwide inpatient database study. J Intensive Care 2023; 11: 4. PMID: 36740697 237. Karami M, Mandigers L, Miranda DDR, et al. DUTCH ECLS Study Group. Survival of patients with acute pulmonary embolism treated with venoarterial extracorporeal membrane oxygenation: A systematic review and meta-analysis. J Crit Care 2021; 64: 245-254. PMID: 34049258 238. Ishiguro S, Nishimura K, Nakamura Y, et al. Pitfall of percutaneous cardiopulmonary support for acute massive pulmonary embolism. Circ J 2007; 71: 1657-1658. PMID: 17895568 239. JRC蘇生ガイドラインALS作業部会.肺血栓塞栓症による心停止.日本蘇生協議会 監修.JRC蘇生ガイドライン2020.医学書院2021:108-109. 240. Goldhaber SZ, Kessler CM, Heit J, et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1988; 332: 293- 298. PMID: 2899718 241. Daniels LB, Parker JA, Patel SR, et al. Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism. Am J Cardiol 1997; 80: 184-188. PMID: 9230156 242. Chatterjee S, Chakraborty A, Weinberg I, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA 2014; 311: 2414-2421. PMID: 24938564 243. Jerjes-Sanchez C, Ramírez-Rivera A, de Lourdes García M, et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: A randomized controlled trial. J Thromb Thrombolysis 1995; 2: 227-229. PMID: 10608028 244. Meyer G, Vicaut E, Danays T, et al. PEITHO Investigators. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med 2014; 370: 1402-1411. PMID: 24716681 245. Niwa A, Nakamura M, Harada N, et al. Observational investigation of thrombolysis with the tissue-type plasminogen activator monteplase for acute pulmonary embolism in Japan. Circ J 2012; 76: 2471-2480. PMID: 22785619 246. Sharifi M, Bay C, Skrocki L, et al. “MOPETT” Investigators. Moderate pulmonary embolism treated with thrombolysis (from the "MOPETT" Trial). Am J Cardiol 2013; 111: 273-277. PMID: 23102885 247. Wang C, Zhai Z, Yang Y, et al. China Venous Thromboembolism (VTE) Study Group. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest 2010; 137: 254-262. PMID: 19741062 248. Amini S, Bakhshandeh H, Mosaed R, et al. Efficacy and safety of different dosage of recombinant tissue-type plasminogen activator (rt-PA) in the treatment of acute pulmonary embolism: A systematic review and meta-analysis. Iran J Pharm Res 2021; 20: 441-454. PMID: 34567173 249. Kline JA, Nordenholz KE, Courtney DM, et al. Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial. J Thromb Haemost 2014; 12: 459- 468. PMID: 24484241 250. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1960; 275: 1309-1312. PMID: 13797091 251. Bjornsson TD, Wolfram KM, Kitchell BB. Heparin kinetics determined by three assay methods. Clin Pharmacol Ther 1982; 31: 104- 113. PMID: 7053298 252. Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. Ann Intern Med 1993; 119: 874-881. PMID: 8214998 253. Büller HR, Davidson BL, Decousus H, et al. Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349: 1695-1702. PMID: 14585937 254. Büller HR, Davidson BL, Decousus H, et al. Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140: 867-873. PMID: 15172900 255. Nakamura M, Okano Y, Minamiguchi H, et al. Multidetector-row

computed tomography-based clinical assessment of fondaparinux for treatment of acute pulmonary embolism and acute deep vein thrombosis in Japanese patients. Circ J 2011; 75: 1424-1432. PMID: 21512258